CareDx Profiles AlloSeq Suite of NGS Products at ASHI
Expands portfolio with three new kitted transplant products launching in 2019
Delivers new insights into the clinical Transplantome by incorporating HLA plus additional genes contributing to successful transplant outcomes
Enables global access for laboratories to assess organ health by measuring donor-derived cell-free DNA associated with allograft injury
The three new NGS laboratory products launching in 2019 are:
- AlloSeq HLA – The Next Generation of Transplant Matching with Full HLA Gene Coverage, Additional Gene Content and Streamlined Workflow
- AlloSeq cfDNA –
Enabling Global Laboratoriesto Assess Organ Healthby Measuring Donor-Derived Cell-Free DNA Associated with Allograft Injury
- AlloSeq BMT – Simplified Workflow and Automated Analysis for Chimerism Testing
“Following the exclusive Illumina NGS transplantation product distribution and development agreement,
“There is great excitement over the performance benefits of AlloSeq HLA, with complete gene coverage and additional panel content delivering outstanding matching information,” said Maria Bettinotti, Ph.D., D(ABHI), FACMG,
“CareDx’s AlloSeq cfDNA kits enable the surveillance of kidney transplant grafts in a quantitative manner, reducing the need for unnecessary invasive procedures and improving patient care. We are very excited to be an early access site for AlloSeq cfDNA and look forward to assessing the clinical implications and the benefits this kit will bring to our transplant patients,” said
For more information, please visit www.CareDx.com.
Forward Looking Statements
This press release contains forward-looking statements about our business, research, development and commercialization efforts. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks associated with successful research, development and planned commercialization of our technologies, that are described in our filings with the
Chief Commercial Officer
Integrated Corporate Relations, Inc.
Source: CareDx, Inc.